Flagship unveils Cygnal, a nervy take on cancer, inflammation

Flagship’s Cygnal is deploying $65M to drug neurological drivers of cancer, inflammation

Cygnal Therapeutics Inc. believes overlooked corners of neurobiology could unlock therapeutic strategies in cancer, inflammation and beyond. With $65 million from Flagship Pioneering and other undisclosed investors, the company launched Tuesday to advance two candidates discovered via its “exoneural biology” platform.

The company’s founding thesis is that the nervous system, particularly the peripheral nervous system (PNS), contributes to the pathology of a much wider range of diseases than those traditionally

Read the full 699 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE